Family Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31.1K | Sell |
184
-916
| -83% | -$157K | ﹤0.01% | 283 |
|
|
2025
Q4 | $186K | Hold |
1,100
| – | – | 0.02% | 236 |
|
|
2025
Q3 | $159K | Hold |
1,100
| – | – | 0.02% | 218 |
|
|
2025
Q2 | $139K | Sell |
1,100
-433
| -28% | -$53.2K | 0.02% | 190 |
|
|
2025
Q1 | $196K | Sell |
1,533
-362
| -19% | -$49.1K | 0.03% | 174 |
|
|
2024
Q4 | $251K | Sell |
1,895
-55
| -3% | -$7.73K | 0.04% | 144 |
|
|
2024
Q3 | $284K | Sell |
1,950
-203
| -9% | -$29.4K | 0.05% | 139 |
|
|
2024
Q2 | $296K | Sell |
2,153
-3,068
| -59% | -$410K | 0.05% | 121 |
|
|
2024
Q1 | $716K | Buy |
5,221
+1,658
| +47% | +$226K | 0.13% | 84 |
|
|
2023
Q4 | $484K | Buy |
3,563
+3,466
| +3,573% | +$423K | 0.1% | 89 |
|
|
2023
Q3 | $11.9K | Hold |
97
| – | – | ﹤0.01% | 151 |
|
|
2023
Q2 | $12.3K | Hold |
97
| – | – | ﹤0.01% | 156 |
|
|
2023
Q1 | $12.5K | Hold |
97
| – | – | ﹤0.01% | 146 |
|
|
2022
Q4 | $12.7K | Hold |
97
| – | – | ﹤0.01% | 165 |
|
|
2022
Q3 | $11K | Hold |
97
| – | – | ﹤0.01% | 152 |
|
|
2022
Q2 | $11K | Sell |
97
-200
| -67% | -$23.7K | ﹤0.01% | 165 |
|
|
2022
Q1 | $39K | Hold |
297
| – | – | 0.01% | 160 |
|
|
2021
Q4 | $45K | Hold |
297
| – | – | 0.01% | 171 |
|
|
2021
Q3 | $48K | Hold |
297
| – | – | 0.01% | 166 |
|
|
2021
Q2 | $49K | Hold |
297
| – | – | 0.01% | 187 |
|
|
2021
Q1 | $45K | Buy |
297
+200
| +206% | +$31.8K | 0.01% | 157 |
|
|
2020
Q4 | $15K | Hold |
97
| – | – | 0.01% | 166 |
|
|
2020
Q3 | $13K | Hold |
97
| – | – | 0.01% | 122 |
|
|
2020
Q2 | $13K | Hold |
97
| – | – | 0.01% | 156 |
|
|
2020
Q1 | $10K | Buy |
97
+67
| +223% | +$7.71K | 0.01% | 153 |
|
|
2019
Q4 | $4K | Sell |
30
-472
| -94% | -$52.7K | ﹤0.01% | 184 |
|
|
2019
Q3 | $50K | Hold |
502
| – | – | 0.02% | 165 |
|
|
2019
Q2 | $55K | Buy |
+502
| New | +$53.4K | 0.02% | 155 |
|
Other funds holding IBB
CB
